期刊文献+

选择性雄激素受体调节子的开发及其治疗应用 被引量:1

下载PDF
导出
摘要 雄激素控制着广泛的生理学功能.雄激素受体作为调节雄激素多种生物学作用的甾体类受体,是一种配基诱导的转录因子.雄激素信号系统的异常导致了从性别确定和性征发育到精神和情感失常的许多紊乱.雄激素替代治疗能改善许多临床症状,包括性腺机能低下与骨质疏松,但由于疗效不高和缺少方便给药的安全制剂而受到限制.最近甾体类受体和选择性受体调节子的基因调控技术,为选择性雄激素受体调节子能否解答现行雄激素治疗中存在的问题,提供了验证的机会.配基化的雄激素受体转录引发复合物的组成决定了基因调控的特异性,设计用于引发组织和启动子特异基因转录的合成配基提供了开发更有效的雄激素治疗的希望.建立能预测合成配基活性的测试方法是选择性雄激素受体调节子开发的关键.化合物筛选的高效率和基因指纹技术的进步,如微阵列技术和蛋白质组学,将加速有效的选择性受体调节子鉴定.
作者 Fang Chen(
出处 《中华男科学杂志》 CAS CSCD 2002年第3期162-168,共7页 National Journal of Andrology
  • 相关文献

参考文献45

  • 1[1]Vermeulen A. Androgen replacement therapy in the aging male--a critical evaluation[J]. J Clin Endocrinol Metab,2001,86(6):2380~2390.
  • 2[2]Basaria S, Wahlstrom JT, Dobs AS. Anabolic-androgenic steroid therapy in the treatment of chronic diseases[J]. J Clin Endocrinol Metab,2001, 86(11):5108~5117.
  • 3[3]Wilson JD. The role of androgens in male gender role behavior[J]. Endocr Rev,1999,20(5):726~737.
  • 4[4]Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium[J]. J Clin Endocrinol Metab,1999,84(10): 3459~3462.
  • 5[5]Miller KK. Androgen deficiency in women[J]. J Clin Endocrinol Metab,2001,86(6):2395~2401.
  • 6[6]McDonnell DP. The molecular pharmacology of SERMs[J]. Trends Endocrinol Metab,1999,10(8): 301~311.
  • 7[7]Schmidt A, Harada S, Rodan GA. Anabolic steroid effects on bone in women[M]. The principles of bone biology, 2001. 2nd ed Vol( 2):1455~1466 .
  • 8[8]McPhaul MJ, Young M. Complexities of androgen action[J]. J Am Acad Dermatol ,2001,45(3 suppl):S87~S94.
  • 9[9]Chang C, Saltzman A, Yeh S, et al. Androgen receptor: an overview[J]. Crit Rev Eukaryot Gene Expr,1995,5(2):97~125 .
  • 10[10]Olefsky JM. Nuclear receptor minireview series[J]. J Biol Chem,2001, 276(40):36863~36864.

同被引文献17

  • 1郭应禄,李宏军.男性更年期综合征[J].中华男科学杂志,2004,10(8):563-566. 被引量:76
  • 2李江源,李小鹰,李明,张高魁,马芳玲,刘志民,张南雁,孟萍.中国健康男子迟发性睾丸功能减退的症状评价[J].中华男科学杂志,2007,13(4):320-323. 被引量:12
  • 3Katharina M,Schragla,Guro Forsdahlb,et al.Novel pathway for the synthesis of arylpropionamide-derived selective androgen receptor modulator (SARM) metabolites of andarine and ostarine[J].Tetrahedron Letters 2013 (54) 2239-2242.
  • 4Xu WH,Zheng W,Xiang YB,et al.Soya food intake and risk of endometrial cancer among Chinese women in Shanghai:population based case-control study.[J] BMJ,2004,328 (7451):1285.
  • 5Wang C,Nieschlag E,Swerdloff R,et al.Investigation,treatment and monitoring of late-onset hypogonadism in males[J].Int J Androl,2009,32(1):1-10.
  • 6Wylie K,Froggatt N.Late-onset hypogonadism,sexuality and fertility[J].Hum Fertil (Camb),2010,13(3):126-133.
  • 7Bassil N,Morley JE.Late-onset hypogonadism:a review[J].Clin Geriatr Med,2010,26(2):197-222.
  • 8Permpongkosol S,Tantirangsee N,Ratana-Olarn K.Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate:effect s on body composition,lipids,and psychosexual complaints[J].J Sex Med,2010,7(11):3765-3774.
  • 9Amano T,Imao T,Takemae K,et al.Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients[J].Aging Male,2010,13(4):242-246.
  • 10Tsujimura A,Takada S,Matsuoka Y,et al.Clinical trial of treatment with saikokaryukotsuboreito for eugonadal patients with late-onset hypogonadism-related symptoms[J].Aging Male,2008,11(2):95-99.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部